a Division of Urology, Department of Surgery, Queen Elizabeth Hospital, Hong Kong, China; b Division of Urology, Department of Surgery, Tuen Mun Hospital, Hong Kong, China
Metabolic syndrome and benign prostatic hyperplasia:An update
a Division of Urology, Department of Surgery, Queen Elizabeth Hospital, Hong Kong, China; b Division of Urology, Department of Surgery, Tuen Mun Hospital, Hong Kong, China
摘要 Metabolic syndrome (MetS) is a cluster of metabolic abnormalities related to central adiposity and insulin resistance. Its importance is increasingly recognized as it associates with increased risks of metabolic and cardiovascular diseases. These metabolic aberrations of MetS may lead to development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in men. A 26.5%-55.6% prevalence of MetS in men with LUTS was reported in worldwide studies. Although the exact biological pathway is not clear yet, insulin resistance, increased visceral adiposity, sex hormone alterations and cellular inflammatory reactions played significant roles in the related pathophysiological processes. Clinician should recognize the cardiovascular and metabolic impacts of MetS in men with LUTS, early risk factors optimization and use of appropriate medical therapy may possibly alter or slower the progression of LUTS/BPH, and potentially avoid unnecessary morbidities and mortalities from cardiovascular and metabolic diseases for those men.
Abstract: Metabolic syndrome (MetS) is a cluster of metabolic abnormalities related to central adiposity and insulin resistance. Its importance is increasingly recognized as it associates with increased risks of metabolic and cardiovascular diseases. These metabolic aberrations of MetS may lead to development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) in men. A 26.5%-55.6% prevalence of MetS in men with LUTS was reported in worldwide studies. Although the exact biological pathway is not clear yet, insulin resistance, increased visceral adiposity, sex hormone alterations and cellular inflammatory reactions played significant roles in the related pathophysiological processes. Clinician should recognize the cardiovascular and metabolic impacts of MetS in men with LUTS, early risk factors optimization and use of appropriate medical therapy may possibly alter or slower the progression of LUTS/BPH, and potentially avoid unnecessary morbidities and mortalities from cardiovascular and metabolic diseases for those men.
[1] Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50. [2] De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012;61:560-70. [3] Department of Noncommunicable Disease Surveillance. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Geneva:World Health Organization; 1999. p32-3. [4] Zimmet P, Alberti KGM, Ríos MS. A new international diabetes federation worldwide definition of the metabolic syndrome:the rationale and the results. Rev Esp Cardiol 2005;58:1371-6. [5] Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3. [6] Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national Cholesterol Education Program (NCEP) expert Panel on Detection, Evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel Ⅲ). JAMA 2001;285:2486-97. [7] Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome:an american heart association/national heart, lung and blood Institute scientific statement. Circulation 2005;112:2735-52. [8] Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7. [9] Alberti KG, Zimmet P, Shaw J. IDF epidemiology task force consensus group. The metabolic syndrome-a new worldwide definition. Lancet 2005;366:1059-62. [10] Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and waist:hipratio as predictors of cardiovascular riskda review of the literature. Eur J Clin Nutr 2010;64:16-22. [11] Seidell JC. Waist circumference and waist/hip ratio in relation to all-cause mortality, cancer and sleep apnea. Eur J Clin Nutr 2010;64:35-41. [12] Diaz VA, Mainous 3rd AG, Baker R, Carnemolla M, Majeed A. How does ethnicity affect the association between obesity and diabetes? Diabet Med 2007;24:1199-204. [13] Obesity in Asia Collaboration, Huxley R, Barzi F, Lee CM, Lear S, Shaw J, et al. Waist circumference thresholds provide an accurate and widely applicable method for the discrimination of diabetes. Diabetes Care 2007;30:3116-8. [14] Huxley R, James WP, Barzi F, Patel JV, Lear SA, Suriyawongpaisal P, et al. Ethnic comparisons of the crosssectional relationships between measures of body size with diabetes and hypertension. Obes Rev 2008;9(Suppl 1):53-61. [15] Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL. Visceral adipose tissue accumulation differs according to ethnic background:results of the Multicultural Community Health Assessment Trial (M-CHAT). Am J Clin Nutr 2007;86:353-9. [16] Kagawa M, Binns CB, Hills AP. Body composition and anthropometry in Japanese and Australian Caucasian males and Japanese females. Asia Pac J Clin Nutr 2007;16(Suppl 1):31-6. [17] Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157-62. [18] Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES Ⅲ). Int J Obes Lond 2005;29:310-6. [19] Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the metabolic syndrome:results from the Boston area community health survey. J Urol 2009;182:616-25. [20] DiBello JR, Ioannou C, Rees J, Challacombe B, Maskell J, Choudhury N, et al. Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia:a large, cross sectional, UK epidemiological study. BJU Int 2016;117:801-8. [21] Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132-8. [22] Park HK, Lee HW, Lee KS, Byun SS, Jeong JS, Hong SK, et al. Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population. Urology 2008;72:556-60. [23] Jeong JH, Kim ET, Kim DK. Association of metabolic syndrome and benign prostate enlargement in young Korean males. Korean J Urol 2011;52:757-62. [24] Ohgaki K, Hikima N, Horiuchi K, Kondo Y. Association between metabolic syndrome and male lower urinary tract symptoms in Japanese subjects using three sets of criteria for metabolic syndrome and international prostate symptom score. Urology 2011;77:1432-8. [25] Yang TK, Hsieh JT, Chen SC, Chang HC, Yang HJ, Huang KH. Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup. Urology 2012;80:1093-7. [26] Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, et al. Metabolic syndrome and benign prostatic enlargement:a systematic review and meta-analysis. BJU Int 2015;115:24-31. [27] Russo GI, Castelli T, Urzì D, Privitera S, Fragalà E, La Vignera S, et al. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components:a systematic review and meta-analysis. Aging Male 2015;18:207-16. [28] Zou C, Gong D, Fang N, Fan Y. Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol 2016;34:281-9. [29] Kwon H, Kang HC, Lee JH. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms. Urology 2013;81:1325-9. [30] Doǧan Y, Uruç F, Aras B, Şahin A, Kıvrak M, Ürkmez A, et al. The relationships between metabolic syndrome, erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia. Turk J Urol 2015;41:7-12. [31] Pan JG, Jiang C, Luo R, Zhou X. Association of metabolic syndrome and benign prostatic hyperplasia in Chinese patients of different age decades. Urol Int 2014;93:10-6. [32] Zhang X, Zeng X, Liu Y, Dong L, Zhao X, Qu X. Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 2014;93:214-9. [33] Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer:another aspect of the insulin-resistance syndrome? Obes Rev 2002;3:303-8. [34] Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003;35:694-704. [35] Haffner SM. Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance:epidemiological and clinical correlation. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S56-8. [36] Hautanen A. Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord 2000; 24(Suppl 2):S64-70. [37] Peehl DM, Cohen P, Rosenfeld RG. The role of insulin-like growth factors in prostate biology. J Androl 1996;17:2-4. [38] Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK, et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002;52:98-105. [39] Stattin P, Kaaks R, Riboli E, Ferrari P, Dechaud H, Hallmans G. Circulating insulin-like growth factor-I and benign prostatic hyperplasia:a prospective study. Scand J Urol Nephrol 2001; 35:122-6. [40] Sarma AV, Parsons JK, McVary K, Wei JT. Diabetes and benign prostatic hyperplasia/lower urinary tract symptomsdwhat do we know? J Urol 2009;182(6 Suppl):S32-7. [41] Landsberg L. Diet, obesity and hypertension:an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986;61:1081-90. [42] Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151-8. [43] Eom CS, Park JH, Cho BL, Choi HC, Oh MJ, Kwon HT. Metabolic syndrome and accompanying hyperinsulinemia have favorable effects on lower urinary tract symptoms in a generally healthy screened population. J Urol 2011;186:175-9. [44] Lotti F, Corona G, Vignozzi L, Rossi M, Maseroli E, Cipriani S, et al. Metabolic syndrome and prostate abnormalities in male subjects of infertile couples. Asian J Androl 2014;16:295-304. [45] Vignozzi L, Gacci M, Santi R, Corona G, Morelli A, Rastrelli G, et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013;73:789-800. [46] Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidaemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006;370:89-93. [47] Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003;157:906-14. [48] Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men:the HUNT study. BJU Int 2005;96:88-92. [49] Kupelian V, Araujo AB, Wittert GA, McKinlay JB. Association of moderate to severe lower urinary tract symptoms with incident type 2 diabetes and heart disease. J Urol 2015;193:581-6. [50] Cohen PG. Abdominal obesity and intra-abdominal pressure:a new paradigm for the pathogenesis of the hypogonadalobesity-BPH-LUTS connection. Horm Mol Biol Clin Investig 2012;11:317-20. [51] Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2:231-7. [52] Reaven GM. The metabolic syndrome:time to get off the merry go-round? J Intern Med 2011;269:127-36. [53] Duvnjak L, Duvnjak M. The metabolic syndromedan ongoing story. J Physiol Pharmacol 2009;60(Suppl 7):19-24. [54] Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metabol 2006;91:2562-8. [55] Mondul AM, Giovannucci E, Platz EA. A prospective study of obesity, and the incidence and progression of lower urinary tract symptoms. J Urol 2014;191:715-21. [56] Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Tubaro A, Vignozz L, et al. Central obesity is predictive of persistent storage lower urinary tract symptoms (LUTS) after surgery for benign prostatic enlargement:results of a multicentre prospective study. BJU Int 2015;116:271-7. [57] Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol 2010;12:157-80. [58] Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis KK, et al. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES Ⅲ). Urology 2007;69:708-13. [59] Shibata Y, Ito K, Suzuki K, Nakano K, Fukabori Y, Suzuki R, et al. Simultaneous quantitative analysis of prostate sex steroids and comparison with human prostatic histological composition. Prostate 2000;42:45-55. [60] Sciarra F, Toscano V. Role of estrogens in human benign prostatic hyperplasia. Arch Androl 2000;44:213-20. [61] Hsing AW. Hormones and prostate cancer:what's next? Epidemiol Rev 2001;23:42-58. [62] Walsh PC, Wilson JD. The induction of prostatic hypertrophy in the dog with and rostanediol. J Clin Invest 1976;57:1093-7. [63] Martin S, Lange K, Haren MT, Taylor AW, Wittert G. Members of the Florey Adelaide Male Ageing Study. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. J Urol 2014;191:130-7. [64] Chiu YL, Kao S, Lin HC, Liu SP, Huang CY. Benign prostatic enlargement is not associated with diabetes:a populationbased study. Andrology 2015;3:933-6. [65] Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 2008;101:313-8. [66] Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003. [67] Russo GI, Castelli T, Urzì D, Privitera S, Fragalà E, La Vignera S, et al. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components:a systematic review and meta-analysis. Aging Male 2015;18:207-16. [68] Penna G, Mondaini N, Amuchastegui S, Degli Innocent S, Carini M, Giubilei G, et al. Seminal plasma cytokines and chemokines in prostate inflammation:interleukin-8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007;51:524-33. [69] Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009;20:182-9. [70] Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES Ⅲ). Prostate 2005;62:27-33. [71] Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2009;55:864-73. [72] De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer:the role of inflammation. Eur Urol 2011;60:106-17. [73] Briganti A, Capitanio U, Suardi N, Gallina A, Salonia A, Bianchi M, et al. Benign prostatic hyperplasia and its aetiologies. Eur Urol Suppl 2009;8:865-71. [74] Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006;175:1422-6. [75] Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia:results from the prostate cancer prevention trial. Am J Epidemiol 2010;171:571-82. [76] Liao CH, Chung SD, Kuo HC. Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment. Urology 2011;78:1373-8. [77] Hung SF, Chung S, Kuo HC. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS One 2014;9:e85588. [78] Kim JH, Doo SW, Yang WJ, Song YS, Kwon SS. Association between high-sensitivity C-reactive protein and lower urinary tract symptoms in healthy Korean populations. Urology 2015;86:139-44. [79] Kozlowski R, Kershen RT, Siroky MB, Krane RJ, Azadzoi KM. Chronic ischaemia alters prostate structure and reactivity in rabbits. J Urol 2001;165:1019-26. [80] Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia:a new metabolic disease? J Endocrinol Invest 2014;37:313-22. [81] Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 2016;13:108-19. [82] Gacci M, Corona G, Sebastianelli A, Serni S, De Nunzio C, Maggi M, et al. Male lower urinary tract symptoms and cardiovascular events:asystematic review and meta-analysis. Eur Urol 2016;70:788-96. [83] Russo GI, Castelli T, Privitera S, Fragala E, Favilla V, Reale G, et al. Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptoms. BJU Int 2015;116:791-6. [84] Lee RK, Chung D, Chughtai B, Te AE, Kaplan SA. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int 2012;110:540-5. [85] Zou C, Gong D, Fang N, Fan Y. Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol 2016;34:281-9. [86] Penson DF, Munro HM, Signorello LB, Blot WJ, Fowke JH. Urologic Diseases in America Project. Obesity, physical activity and lower urinary tract symptoms:results from the Southern Community Cohort Study. J Urol 2011;186:2316-22. [87] Parsons JK, Messer K, White M, Barrett-Connor E, Bauer DC, Marshall LM, et al. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men:the Osteoporotic Fractures in Men study. Eur Urol 2011;60:1173-80. [88] Choo MS, Han JH, Shin TY, Ko K, Lee WK, Cho ST, et al. Alcohol, smoking, physical activity, protein, and lower Urinary tract symptoms:prospective longitudinal cohort. Int Neurourol J 2015;19:197-206. [89] Maserejian NN, Kupelian V, Miyasato G, McVary KT, McKinlay JB. Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J Urol 2012;188:490-5. [90] Smith DP, Weber MF, Soga K, Korda RJ, Tikellis G, Patel MI, et al. Relationship between lifestyle and health factors and severe lower urinary tract symptoms (LUTS) in 106,435 middle-aged and older Australian men:population-based study. PLoS One 2014;9:e109278. [91] Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol 2008;53:1228-35. [92] Wang S, Mao Q, Lin Y, Wu J, Wang X, Zheng X, et al. Body mass index and risk of BPH:a meta-analysis. Prostate Cancer Prostatic Dis 2012;15:265-72. [93] Liu ZM, Wong CK, Chan D, Tse LA, Yip B, Wong SY. Fruit and vegetable intake in relation to lower urinary tract symptoms and erectile dysfunction among Southern Chinese elderly men:a 4-year prospective study of Mr OS Hong Kong. Med Baltim 2016;95:e2557. [94] Rohrmann S, Giovannucci E, Willett WC, Platz EA. Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr 2007;85:523-9. [95] Maserejian NN, Giovannucci EL, McVary KT, McKinlay JB. Dietary, but not supplemental, intakes of carotenoids and vitamin C are associated with decreased odds of lower urinary tract symptoms in men. J Nutr 2011;141:267-73. [96] Wong SY, Woo J, Leung JC, Leung PC. Depressive symptoms and lifestyle factors as risk factors of lower urinary tract symptoms in Southern Chinese men:a prospective study. Aging Male 2010;13:113-9. [97] St Sauver JL, Jacobsen SJ, Jacobson DJ, McGree ME, Girman CJ, Nehra A, et al. Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int 2011;107:443-50. [98] Russo GI, Castelli T, Urzi D, Privitera S, Fragala E, La Vignera S, et al. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components:a systematic review and meta-analysis. Aging Male 2015;18:207-16. [99] Gao Y, Wang M, Zhang H, Tan A, Yang X, Qin X, et al. Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey. Urology 2012;79:194-201. [100] Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the metabolic syndrome:results from the Boston Area Community Health Survey. J Urol 2009;182:616-25. [101] Hall SA, Chiu GR, Link CL, Steers WD, Kupelian V, McKinlay JB. Are statin medications associated with lower urinary tract symptoms in men and women? Results from the Boston Area Community Health (BACH) Survey. Ann Epidemiol 2011;21:149-55. [102] Zhang X, Zeng X, Dong L, Zhao X, Qu X. The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome. World J Urol 2015;33:2071-7. [103] Lee SH, Park TJ, Bae MH, Choi SH, Cho YS, Joo KJ, et al. Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia. Korean J Urol 2013;54:750-5. [104] Stamatiou KN, Zaglavira P, Skolarikos A, Sofras F. The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol 2008; 34:555-62. [105] Mills IW, Crossland A, Patel A, Ramonas H. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol 2007;52:503-9. [106] Mondul AM, Giovannucci E, Platz EA. A prospective study of statin drug use and lower urinary tract symptoms in older men. Am J Epidemiol 2013;178:797-803. [107] Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin:an overview. Clin Sci Lond 2012;122:253-70. [108] Mosli HH, Esmat A, Atawia RT, Shoieb SM, Mosli HA, AbdelNaim AB. Metformin attenuates testosterone-induced prostatic hyperplasia in rats:a pharmacological perspective. Sci Rep 2015;5:15639. [109] Wang Z, Olumi AF. Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation 2011;82:261-71. [110] Russo GI, Cimino S, Fragala E, Privitera S, La Vignera S, Condorelli R, et al. Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction:results from a cross-sectional study. J Sex Med 2014;11:2074-82. [111] Sarma AV, St Sauver JL, Hollingsworth JM, Jacobson DJ, McGree ME, Dunn RL, et al. Diabetes treatment and progression of benign prostatic hyperplasia in communitydwelling black and white men. Urology 2012;79:102-8. [112] Wallner LP, Hollingsworth JM, Dunn RL, Kim C, Herman WH, Sarma AV, et al. Hyperglycemia, hyperinsulinemia, insulin resistance, and the risk of BPH/LUTS severity and progression over time in community dwelling black men:the Flint Men's Health Study. Urology 2013;82:881-6.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
